Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost - effective Purification Technologies
14 Oct 2010 • by Natalie Aster
GBI Research's report, “Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost-effective Purification Technologies”, provides the key market data on Contract Manufacturing Organization (CMO) market for biopharmaceuticals, CMO market for downstream processing, and the reagent market for downstream processing. The report also analyzes the strengths, weaknesses, opportunities, and threats for the key players in the downstream processing of biopharmaceuticals. The report also discusses the key market drivers and barriers for the downstream processing. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the Downstream Processing in Biopharmaceuticals.
Strong Growth is Expected in the CMO Biopharmaceuticals’ Market
The use of CMOs is one of the most significant trends in the healthcare industry, especially in the biopharmaceuticals market. CMOs will be used for most of the processes in the industry. Although the CMO market is not growing much at the moment due to capacity expansions by major companies such as Lonza Group Ltd., and Boehringer Ingelheim and many more. Their focus has been shifted towards setting up new plants, and buying new equipments. These expansion processes indicate the future prospects of the industry. Many experts in the industry have already predicted that the future of the CMO market is bright. Several players from emerging countries are entering the market. Companies are opening up operations in emerging countries such as India, China, and Singapore.
CMO Market Growth Rate for Downstream Processing Will Be Greater Than Overall CMO Market for Biopharmaceuticals
Manufacturing of biopharmaceuticals mainly involve upstream and downstream processing. Major CMOs offer both, manufacturing functions upstream and downstream equally. Except the manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing of biopharmaceutical drugs.
GBI research suggests that the CMO market size for downstream processing is set to grow at a CAGR of 14.9%, which is more than the growth of the overall CMO biopharmaceutical market.
Reagent Market for Downstream Processing
GBI research states that total reagent market (used in downstream processing) has been calculated at $4,301m in 2009. This is expected to grow at the CAGR of 7.1% for the period of 2009-2016 and is expected to reach $6,640m by 2016.
Strong Growth is Expected in the CMO Biopharmaceuticals’ Market
The use of CMOs is one of the most significant trends in the healthcare industry, especially in the biopharmaceuticals market. CMOs will be used for most of the processes in the industry. Although the CMO market is not growing much at the moment due to capacity expansions by major companies such as Lonza Group Ltd., and Boehringer Ingelheim and many more. Their focus has been shifted towards setting up new plants, and buying new equipments. These expansion processes indicate the future prospects of the industry. Many experts in the industry have already predicted that the future of the CMO market is bright. Several players from emerging countries are entering the market. Companies are opening up operations in emerging countries such as India, China, and Singapore.
CMO Market Growth Rate for Downstream Processing Will Be Greater Than Overall CMO Market for Biopharmaceuticals
Manufacturing of biopharmaceuticals mainly involve upstream and downstream processing. Major CMOs offer both, manufacturing functions upstream and downstream equally. Except the manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing of biopharmaceutical drugs.
GBI research suggests that the CMO market size for downstream processing is set to grow at a CAGR of 14.9%, which is more than the growth of the overall CMO biopharmaceutical market.
Reagent Market for Downstream Processing
GBI research states that total reagent market (used in downstream processing) has been calculated at $4,301m in 2009. This is expected to grow at the CAGR of 7.1% for the period of 2009-2016 and is expected to reach $6,640m by 2016.
